XLV declined another 3% last week, closing below its 100-DMA ($140.26) which may now act as near-term resistance. Though we
believe the sector is short-term oversold, it is more likely to chop in a range with the next level of support at ~$136.50, which may
coincide with a rising 200-DMA ($135.66). We continue to recommend an underweight sector positioning given its RS line continues
to fall to new lows.
Author: Raj Gupta
Market View
The U.S. market remains in an Uptrend Under Pressure. Price action remains very volatile as both indices pulled back and are testing their respective 50-DMAs (S&P 500: 5,111, Nasdaq: 16,061). Should both indices close below their 50-DMA, the market status is at risk of being downgraded to Correction. Currently the distribution day count stands at seven and six days on the S&P 500 and Nasdaq, respectively, with two days expiring on each index at the end of next week.
O’Neil Health Care Weekly
XLV was the second worst performing sector (Retail) last week, falling over 3% and breaking 50-DMA support ($144.71) which will
now act as near-term resistance. The next support level is the rising 100-DMA ($139.56). XLV’s RS line (vs. the S&P 500 and Nasdaq)
made a lower low, warranting an underweight sector positioning.
Market View
The U.S. market was shifted to an Uptrend Under Pressure. The S&P 500 and Nasdaq declined ~1.0% and 0.8%, respectively for the week. Both breached and closed below the 21-DMA on Thursday. It was the first time both indices closed below their 21-DMAs since early-January. Indices retook their 21-DMAs on Friday, and if they settle back above for several days, we could shift the market back to Confirmed Uptrend. Otherwise, another break below leaves support at rising 50-DMAs (5,083/15,980). The distribution day count stands at five and eight, respectively, with two expiring on the Nasdaq next week.
O’Neil Health Care Weekly
XLV gained 1.6% last week, after finding support at its 21-DMA ($145.90). Overall absolute action remains positive with resistance at
the prior high of $148.27. Though its RS line (vs. S&P 500 and Nasdaq) bounced off lows, the overall trend still remains down,
warranting an equal-to under-weight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. Indices closed mixed, with the S&P 500 rising 0.4%, and the Nasdaq declining
marginally. Both indices remain at or within 1% of their all-time highs. Short-term support for both indices remains at the 10-DMA
(5,207/16,292), followed by the rising 21-DMA (5,166/16,197). The distribution day count on the indices remains at four and eight,
respectively, with one expiring on each next week.
O’Neil Health Care Weekly
XLV continues to trade relatively flat, still consolidating gains ~2% off highs and above 50-DMA ($143.74) support. Despite absolute
price action remaining intact, its RS line (vs. S&P 500 and Nasdaq) made another new low last week, warranting an under-to equalweight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and the Nasdaq gained +2% and touched another new all-time
high. Short-term support for both indices remains at their respective 10-DMA (5,184/16,242) followed by the rising 21-DMA
(5,136/16,117). The distribution day count declined to four and seven, respectively, with another day set to expire on each index after
the close on Monday.
O’Neil Health Care Weekly
XLV has been consolidating for four weeks, pulling back 73bps last week and now narrowly below its 21-DMA ($145.56). Support
below this level is the rising 50-DMA ($143.20). We continue to recommend an equal-weight sector positioning given its RS line
remains in a longer-term downtrend.
Market View
The U.S. market remains in a